GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

China Meheco Group Co 600056.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

8.86

-0.78%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About China Meheco Group Co

Its shares trade on Shanghai under the ticker 600056.SS. It has been listed since 15 May 1997. In the fiscal year to 31 December 2025, it reported revenue of CN¥35.36bn and net income of CN¥473.2m. At that date it held total assets of CN¥36.87bn and shareholders' equity of CN¥11.84bn.

China Meheco Group Co., Ltd. engages in the wholesale of medicine, drugs, and Chinese herbal medicine. The company is headquartered in Beijing, Beijing. Industrial Pharmaceutical segment mainly involves in the manufacture and distribution of chemical preparations, chemical bulk drugs, biological products, Chinese patent medicine, herbal decoction pieces and other pharmaceutical products. Commercial Pharmaceutical segment is mainly engaged in the wholesale and distribution of pharmaceuticals and medical devices. Trading segment is mainly engaged in the international exporting business and medical resourcing introduction.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Providers & Services
Listed since
15 May 1997
Employees
8,313
Website
meheco.com ↗

Leadership

Pay as last reported

  • Mr. Guang YangChairman of the Board, since 2024
  • Ms. Xiaohong GeChief Accounting OfficerCN¥482,100
  • Mr. Jian ZhangGeneral CounselCN¥1.1m
  • Ms. Huidong HuGeneral Manager, Director, since 2021CN¥1.3m
  • Mr. Jiaqing HongDeputy General ManagerCN¥1.1m
  • Mr. Heping LuAssistant to General ManagerCN¥795,400
  • Mr. Huibo ZhangAssistant to General ManagerCN¥1.3m
  • Mr. Jinghua YuanSecretary of the BoardCN¥1.4m
  • Mr. Lingyun CheDirector
  • Mr. Yuandong LiuDirector
  • Mr. Chaoyin TongDirector
  • Mr. Xingbing ZhouStaff Elected DirectorCN¥1.6m

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
60
Environment
83
Social
53
Governance
44
Women in the workforce
45.06%
Carbon reduction policy
Yes
Human rights policy
Yes

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Beijing with a focus on health care sector
  • Employs 8,313 full-time employees
  • Operates across multiple segments including industrial, commercial, and trading pharmaceutical activities

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • Reliance on traditional pharmaceutical wholesale and distribution models
  • No mention of digital transformation or online platform capabilities

Opportunities

  • Expansion into international markets through the trading segment
  • Growth potential in the health care sector in China
  • Potential for diversification into new pharmaceutical product lines

Threats

  • Competition from other pharmaceutical companies in China
  • Regulatory changes in the health care industry
  • Dependence on traditional business models facing digital disruption

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.